[Skip to Navigation]
Editorial
July 3, 2018

Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward?

Author Affiliations
  • 1Durham Veterans Affairs Health Services Research and Development Center of Innovation, Durham, North Carolina
  • 2Division of Endocrinology, Duke University Medical Center, Durham, North Carolina
  • 3Department of Population Health Sciences, Duke University Medical Center, Durham, North Carolina
  • 4Division of General Internal Medicine, Duke University Medical Center, Durham, North Carolina
JAMA. 2018;320(1):38-39. doi:10.1001/jama.2018.8033

In spring 2017, the American Diabetes Association tasked a working group with examining soaring insulin list prices,1 which had nearly tripled between 2002 and 2013.2 Because pharmaceutical spending represents a prime contributor to the escalating costs of diabetes care in the United States,2,3 these increases in insulin pricing warranted analysis.

×